These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 10834149)
1. [In vitro activity of faropenem against beta-lactamase producing clinical isolates]. Nishiyama T; Matsuzaki K; Koyama H; Saika T; Hasegawa M; Kobayashi I Jpn J Antibiot; 2000 Mar; 53(3):179-83. PubMed ID: 10834149 [TBL] [Abstract][Full Text] [Related]
2. [In vitro bactericidal activities of new oral penem, faropenem against the various clinical isolates]. Matsuzaki K; Nishiyama T; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J Jpn J Antibiot; 1999 May; 52(5):431-8. PubMed ID: 10480050 [TBL] [Abstract][Full Text] [Related]
3. In vitro investigation of the indirect pathogenicity of beta-lactamase-producing microorganisms in the nasopharyngeal microflora. Kaieda S; Yano H; Okitsu N; Hosaka Y; Okamoto R; Inoue M; Takahashi H Int J Pediatr Otorhinolaryngol; 2005 Apr; 69(4):479-85. PubMed ID: 15763284 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China. Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692 [TBL] [Abstract][Full Text] [Related]
5. [Antimicrobial activities of beta-lactam antibiotics against clinically isolated Haemophilus influenzae]. Takahashi T; Tsujihara Y; Harada M; Shimura H; Takahashi S; Hachiya K; Matsumoto F; Takahashi S Jpn J Antibiot; 1999 Apr; 52(4):292-301. PubMed ID: 10396686 [TBL] [Abstract][Full Text] [Related]
6. Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Critchley IA; Karlowsky JA; Draghi DC; Jones ME; Thornsberry C; Murfitt K; Sahm DF Antimicrob Agents Chemother; 2002 Feb; 46(2):550-5. PubMed ID: 11796376 [TBL] [Abstract][Full Text] [Related]
9. [In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains]. Nasu T; Okamoto K; Nakanishi T; Nishino T Jpn J Antibiot; 1999 Aug; 52(8):541-53. PubMed ID: 10587879 [TBL] [Abstract][Full Text] [Related]
10. Sch 34343: in-vitro antibacterial activity and susceptibility to beta-lactamases. Shannon K; King A; Phillips I J Antimicrob Chemother; 1985 Jun; 15 Suppl C():15-23. PubMed ID: 3897169 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of faropenem and 20 other compounds against beta-lactamase-positive and -negative Moraxella catarrhalis and Haemophilus influenzae isolates and the effect of serum on faropenem MICs. Schmitz FJ; Boos M; Mayer S; Verhoef J; Milatovic D; Fluit AC J Antimicrob Chemother; 2002 Jan; 49(1):220-3. PubMed ID: 11751796 [No Abstract] [Full Text] [Related]
12. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456 [TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability. Cohen MA; Joannides ET; Roland GE; Meservey MA; Huband MD; Shapiro MA; Sesnie JC; Heifetz CL Diagn Microbiol Infect Dis; 1994 Jan; 18(1):31-9. PubMed ID: 8026155 [TBL] [Abstract][Full Text] [Related]
14. Differentiation of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae from other H. influenzae strains by a disc method. Ubukata K; Chiba N; Hasegawa K; Shibasaki Y; Sunakawa K; Nonoyama M; Iwata S; Konno M J Infect Chemother; 2002 Mar; 8(1):50-8. PubMed ID: 11957120 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production. Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715 [TBL] [Abstract][Full Text] [Related]
16. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media. Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681 [TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Hikida M; Itahashi K; Igarashi A; Shiba T; Kitamura M Antimicrob Agents Chemother; 1999 Aug; 43(8):2010-6. PubMed ID: 10428928 [TBL] [Abstract][Full Text] [Related]
18. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)]. Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430 [TBL] [Abstract][Full Text] [Related]
19. [Antibacterial activity of oral Cephems against various clinically isolated strains]. Oshiro T; Fukutomi Y; Takayanagi M; Kusaba K; Nagasawa Z; Aoki Y; Nagayama A Jpn J Antibiot; 2003 Dec; 56(6):681-90. PubMed ID: 15007876 [TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activities of ticarcillin alone and ticarcillin plus clavulanic acid against beta-lactamase producing and non-producing microorganisms. Hsueh PR; Chang SC; Chen YC; Hsu LY; Luh KT; Hsieh WC Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1992 Aug; 25(3):149-59. PubMed ID: 1342000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]